%20(1).webp)

A 71-year-old man is referred with a clear developmental history, impairment across three decades and a structured interview that leaves little real doubt. He takes ramipril and atorvastatin. His clinic blood pressure is 148/88. He asks whether ADHD medication is safe for someone his age.
The honest answer depends on what you check before the first prescription, and on what the evidence can and cannot tell you. This guide sets out what NICE asks for at baseline, the features that need a cardiology opinion, what the product licences say, and how to handle older adults, where the evidence is thinnest. Ongoing monitoring and the annual review are covered separately in our guide to ADHD annual review and physical health monitoring.
NICE guideline NG87 sets out a full baseline assessment before starting ADHD medication. The physical health part includes:
The last item is a history and examination, not the two observations above it. Ask specifically about the symptoms in the next section, and about the family history.
A cardiovascular assessment is a history and an examination. A pulse and a blood pressure reading are only part of it.
NICE is deliberately restrictive here. An ECG is not needed before starting stimulants, atomoxetine or guanfacine unless the person has one of the referral features below, or a coexisting condition being treated with a medicine that may pose an increased cardiac risk.
Ordering one routinely is not a substitute for the history that tells you whether it is indicated. NICE also advises against routine ECGs during treatment unless there is a clinical indication.
NG87 says to refer for a cardiology opinion before starting ADHD medication if any of the following apply:
The last item matters most in older patients, where treated and untreated hypertension are common. The opinion comes before the prescription, not alongside it. A single raised reading in clinic should be repeated before you decide anything, ideally with the patient seated and rested, or with home or ambulatory readings.
A separate set of conditions sits in each product’s Summary of Product Characteristics (SmPC). These are not a matter of clinical weighing, and they differ between medicines, so read the SmPC for the product you intend to use rather than generalising.
A contraindication to one medicine is not a decision not to treat. It is a prompt to discuss the case with a colleague, get cardiology input where needed, and consider a different option. Our overview of the medicines used for ADHD covers the main classes. Guanfacine is not a simple fallback in adults: the Intuniv SmPC licenses it for ages 6 to 17 and states that safety and efficacy in adults have not been established.
Across age groups, the large pooled studies are broadly reassuring. A 2022 meta-analysis by Zhang and colleagues in JAMA Network Open pooled 19 observational studies, with about 3.9 million participants of all ages and a median follow-up of 1.5 years. It found no statistically significant association between ADHD medication and cardiovascular disease overall.
Medicines other than guanfacine do raise blood pressure and heart rate on average, by a small amount. A 2025 network meta-analysis of randomised trials by Farhat and colleagues in The Lancet Psychiatry (since corrected) reached that general conclusion, while noting that trials are short and some people may be affected more than the average suggests. That is the reason for measuring, not assuming.
The picture is less certain after 65. In the Zhang meta-analysis, the older-adult subgroup estimate pointed towards higher risk, but with a confidence interval so wide that it neither shows nor rules out harm.
The strongest signal comes from Tadrous and colleagues, a 2021 Ontario cohort of 6,457 adults aged 66 and over who started a stimulant, matched with 24,853 non-users. Starting a stimulant was associated with a higher risk of a combined outcome of heart attack, stroke or TIA, or ventricular arrhythmia in the first 30 days (hazard ratio 1.4, 95% CI 1.1 to 1.8). That combined signal was not significant at 180 days or a year, although the ventricular arrhythmia signal was still present at 180 days. This is observational data, so confounding is likely, but it is the best direct evidence there is.
The licences reflect the same uncertainty. The Concerta XL SmPC states that methylphenidate should not be used in the elderly, because safety and efficacy have not been established and it has not been studied in ADHD above 65. The Elvanse Adult SmPC says data in elderly patients are limited, so a thorough pre-treatment evaluation and ongoing monitoring of blood pressure and cardiovascular status are required.
So prescribing for a patient like the 71-year-old above is a specialist decision, not a routine one. Where methylphenidate is considered, it is outside the terms of its licence for this age group, so record the reasoning, the alternatives considered and the patient’s informed agreement. For more on assessing ADHD in later life, see our guide to late diagnosis of ADHD in adults over 50.
NICE asks for heart rate and blood pressure to be checked before and after each dose change and every six months. If a person has a sustained resting heart rate above 120, an arrhythmia, or a clinically significant rise in systolic blood pressure on two occasions, reduce the dose and refer.
Where the Tadrous signal applies, six-monthly checks will not see a risk that sits in the first month. For older adults and anyone with cardiovascular risk factors, a defensible plan concentrates attention early:
Our adult ADHD titration protocol sets out how dose steps and reviews fit together.
Do not pick the most reassuring study and stop there. A defensible explanation is that, across large studies, ADHD medication has not been shown to raise cardiovascular risk overall, and the average effect on blood pressure and heart rate is small.
Then say the rest: in people over 65 the evidence is limited, one good study found more events in the first month after starting, and that is why the checks before starting are thorough and the early reviews are frequent. Record that conversation. It is also a good time to check other medicines the patient takes, and whether they plan to travel, for which our guide to travelling with ADHD medication covers the paperwork.
No. NICE says an ECG is only needed if one of the cardiology referral features is present, or if a coexisting condition is treated with a medicine that may pose an increased cardiac risk.
It can be done, but it is a specialist decision. The methylphenidate SmPC says it should not be used in the elderly, and the lisdexamfetamine SmPC asks for thorough pre-treatment evaluation and ongoing monitoring because data are limited. Document the reasoning and monitor closely in the first weeks.
NICE says to seek a cardiology opinion first if blood pressure is classified as hypertensive for adults. Severe hypertension is a contraindication to methylphenidate, and moderate to severe hypertension is a contraindication to lisdexamfetamine. A single raised reading should be repeated before you decide.
Averages are what a pre-prescription check exists to look past. The patient with heart disease nobody has found yet does not experience the average, and the history, examination and referral list above are how you find them before the first dose rather than after it. Check the current NICE guidance and SmPC at the time you prescribe, as both are updated.
Global ADHD Network’s ADHD prescribing and management course works through initiation, titration and monitoring in more depth. For nurses and pharmacists building prescribing practice, see our guide to ADHD prescribing training.
